Rohto PharmaceuticalLtd Future Growth
Future criteria checks 3/6
Rohto PharmaceuticalLtd is forecast to grow earnings and revenue by 13.5% and 9.7% per annum respectively. EPS is expected to grow by 13.5% per annum. Return on equity is forecast to be 13.1% in 3 years.
Key information
13.5%
Earnings growth rate
13.5%
EPS growth rate
| Personal Products earnings growth | 19.4% |
| Revenue growth rate | 9.7% |
| Future return on equity | 13.1% |
| Analyst coverage | Good |
| Last updated | 13 Nov 2024 |
Recent future growth updates
Rohto Pharmaceutical Co.,Ltd. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Nov 15
Rohto Pharmaceutical Co.,Ltd. Just Missed EPS By 6.8%: Here's What Analysts Think Will Happen Next
Aug 11Recent updates
Rohto Pharmaceutical Co.,Ltd. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Nov 15Rohto Pharmaceutical Co.,Ltd. (TSE:4527) Shares Could Be 25% Below Their Intrinsic Value Estimate
Nov 07These 4 Measures Indicate That Rohto PharmaceuticalLtd (TSE:4527) Is Using Debt Reasonably Well
Oct 20Shareholders Should Be Pleased With Rohto Pharmaceutical Co.,Ltd.'s (TSE:4527) Price
Oct 06Returns At Rohto PharmaceuticalLtd (TSE:4527) Appear To Be Weighed Down
Sep 22Here's Why Rohto PharmaceuticalLtd (TSE:4527) Has Caught The Eye Of Investors
Aug 25Rohto Pharmaceutical Co.,Ltd. Just Missed EPS By 6.8%: Here's What Analysts Think Will Happen Next
Aug 11Does Rohto PharmaceuticalLtd (TSE:4527) Have A Healthy Balance Sheet?
Jul 11Calculating The Fair Value Of Rohto Pharmaceutical Co.,Ltd. (TSE:4527)
Jun 23Unpleasant Surprises Could Be In Store For Rohto Pharmaceutical Co.,Ltd.'s (TSE:4527) Shares
Jun 10Rohto PharmaceuticalLtd (TSE:4527) Has More To Do To Multiply In Value Going Forward
May 14These 4 Measures Indicate That Rohto PharmaceuticalLtd (TSE:4527) Is Using Debt Safely
Apr 03Here's Why We Think Rohto PharmaceuticalLtd (TSE:4527) Is Well Worth Watching
Mar 21Rohto PharmaceuticalLtd (TSE:4527) Is Paying Out A Larger Dividend Than Last Year
Mar 07Estimating The Intrinsic Value Of Rohto Pharmaceutical Co.,Ltd. (TSE:4527)
Feb 26Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 3/31/2027 | 385,886 | 42,047 | 34,525 | 49,092 | 9 |
| 3/31/2026 | 359,807 | 37,843 | 31,513 | 42,143 | 9 |
| 3/31/2025 | 319,225 | 33,655 | 25,109 | 39,214 | 9 |
| 9/30/2024 | 282,053 | 27,263 | 29,380 | 39,441 | N/A |
| 6/30/2024 | 278,025 | 30,328 | N/A | N/A | N/A |
| 3/31/2024 | 270,840 | 30,936 | 25,333 | 34,245 | N/A |
| 12/31/2023 | 263,564 | 30,897 | N/A | N/A | N/A |
| 9/30/2023 | 256,220 | 29,779 | 18,967 | 28,610 | N/A |
| 6/30/2023 | 247,580 | 28,473 | N/A | N/A | N/A |
| 3/31/2023 | 238,664 | 26,377 | 21,016 | 30,924 | N/A |
| 12/31/2022 | 231,887 | 25,722 | N/A | N/A | N/A |
| 9/30/2022 | 218,940 | 23,454 | 15,347 | 26,370 | N/A |
| 6/30/2022 | 209,586 | 23,281 | N/A | N/A | N/A |
| 3/31/2022 | 199,646 | 21,018 | 15,922 | 27,250 | N/A |
| 12/31/2021 | 195,698 | 22,593 | N/A | N/A | N/A |
| 9/30/2021 | 189,302 | 21,321 | 13,846 | 25,427 | N/A |
| 6/30/2021 | 184,961 | 19,537 | N/A | N/A | N/A |
| 3/31/2021 | 181,287 | 16,743 | 9,704 | 20,008 | N/A |
| 12/31/2020 | 179,819 | 13,931 | N/A | N/A | N/A |
| 9/30/2020 | 180,903 | 14,283 | 10,794 | 18,162 | N/A |
| 6/30/2020 | 185,058 | 15,130 | N/A | N/A | N/A |
| 3/31/2020 | 188,327 | 15,410 | 12,607 | 19,040 | N/A |
| 12/31/2019 | 187,006 | 11,490 | N/A | N/A | N/A |
| 9/30/2019 | 186,751 | 9,787 | 16,076 | 20,987 | N/A |
| 6/30/2019 | 184,854 | 8,576 | N/A | N/A | N/A |
| 3/31/2019 | 183,582 | 9,799 | 14,828 | 21,745 | N/A |
| 12/31/2018 | 182,328 | 10,058 | N/A | N/A | N/A |
| 9/30/2018 | 180,503 | 10,959 | 14,057 | 21,530 | N/A |
| 6/30/2018 | 176,543 | 10,454 | N/A | N/A | N/A |
| 3/31/2018 | 171,742 | 9,289 | N/A | 19,154 | N/A |
| 12/31/2017 | 167,286 | 11,699 | N/A | N/A | N/A |
| 9/30/2017 | 161,799 | 11,467 | N/A | 15,750 | N/A |
| 6/30/2017 | 157,557 | 10,913 | N/A | N/A | N/A |
| 3/31/2017 | 154,599 | 10,011 | N/A | 13,428 | N/A |
| 12/31/2016 | 158,115 | 9,705 | N/A | N/A | N/A |
| 9/30/2016 | 160,973 | 8,416 | N/A | 9,355 | N/A |
| 6/30/2016 | 164,467 | 9,143 | N/A | N/A | N/A |
| 3/31/2016 | 167,016 | 9,098 | N/A | 11,324 | N/A |
| 12/31/2015 | 164,639 | 10,591 | N/A | N/A | N/A |
| 9/30/2015 | 161,852 | 9,926 | N/A | 14,694 | N/A |
| 6/30/2015 | 157,167 | 9,311 | N/A | N/A | N/A |
| 3/31/2015 | 151,774 | 8,631 | N/A | 11,292 | N/A |
| 12/31/2014 | 148,167 | 6,608 | N/A | N/A | N/A |
| 9/30/2014 | 146,495 | 8,002 | N/A | 12,684 | N/A |
| 6/30/2014 | 143,900 | 7,676 | N/A | N/A | N/A |
| 3/31/2014 | 143,822 | 8,947 | N/A | 18,661 | N/A |
| 12/31/2013 | 139,613 | 9,183 | N/A | N/A | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 4527's forecast earnings growth (13.5% per year) is above the savings rate (0.3%).
Earnings vs Market: 4527's earnings (13.5% per year) are forecast to grow faster than the JP market (8% per year).
High Growth Earnings: 4527's earnings are forecast to grow, but not significantly.
Revenue vs Market: 4527's revenue (9.7% per year) is forecast to grow faster than the JP market (4.2% per year).
High Growth Revenue: 4527's revenue (9.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 4527's Return on Equity is forecast to be low in 3 years time (13.1%).